AU2001255013A1 - Combination of growth hormone secretagogues and antidepressants - Google Patents

Combination of growth hormone secretagogues and antidepressants

Info

Publication number: AU2001255013A1
Authority: AU; Australia
Prior art keywords: antidepressants; combination; growth hormone; hormone secretagogues; secretagogues
Prior art date: 2000-05-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001255013A

Inventor

Frank Robert Busch

Willard Mckowan Welch

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Products Inc

Original Assignee

Pfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-25

Filing date

2001-05-10

Publication date

2001-12-03

2001-05-10 Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc

2001-12-03 Publication of AU2001255013A1 publication Critical patent/AU2001255013A1/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Neurology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2001255013A 2000-05-25 2001-05-10 Combination of growth hormone secretagogues and antidepressants Abandoned AU2001255013A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20701700P	2000-05-25	2000-05-25
US60207017		2000-05-25
PCT/IB2001/000815 WO2001089570A2 (en)	2000-05-25	2001-05-10	Combination of growth hormone secretagogues and antidepressants

Publications (1)

Publication Number	Publication Date
AU2001255013A1 true AU2001255013A1 (en)	2001-12-03

Family

ID=22768871

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001255013A Abandoned AU2001255013A1 (en)	2000-05-25	2001-05-10	Combination of growth hormone secretagogues and antidepressants

Country Status (17)

Country	Link
US (1)	US20020002137A1 (en)
EP (1)	EP1284753A2 (en)
JP (1)	JP2003534294A (en)
AR (1)	AR028620A1 (en)
AU (1)	AU2001255013A1 (en)
BR (1)	BR0111002A (en)
CA (1)	CA2408036A1 (en)
DO (1)	DOP2001000154A (en)
EC (1)	ECSP014082A (en)
GT (1)	GT200100089A (en)
MX (1)	MXPA02011554A (en)
PA (1)	PA8517701A1 (en)
PE (1)	PE20011262A1 (en)
SV (1)	SV2001000465A (en)
TN (1)	TNSN01076A1 (en)
UY (1)	UY26731A1 (en)
WO (1)	WO2001089570A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7795267B2 (en)	2003-08-29	2010-09-14	Takeda Pharmaceutical Company Limited	Bicyclic piperazine compound having TGR23 antagonistic activity
JP2005306839A (en) *	2003-08-29	2005-11-04	Takeda Chem Ind Ltd	Bicyclic piperazine compound and its use
US20050143350A1 (en) *	2003-11-19	2005-06-30	Seed John C.	Combination drug therapy to treat obesity
EP1757290A1 (en)	2005-08-16	2007-02-28	Zentaris GmbH	Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
PE20080145A1 (en)	2006-03-21	2008-02-11	Janssen Pharmaceutica Nv	TETRAHYDRO-PYRIMIDOAZEPINE AS MODULATORS OF TRPV1
CN101657436A (en)	2007-02-09	2010-02-24	特兰齐姆制药公司	Macrocyclic ghrelin receptor modulators and using method thereof
US8822498B2 (en)	2007-09-13	2014-09-02	Concert Pharmaceuticals, Inc.	Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
JP5562865B2 (en)	2007-12-17	2014-07-30	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	TRPV1 imidazolo-, oxazolo-, and thiazolopyrimidine modulators
EP2431035A1 (en)	2010-09-16	2012-03-21	Æterna Zentaris GmbH	Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
AR086554A1 (en)	2011-05-27	2014-01-08	Novartis Ag	DERIVATIVES OF PIPERIDINE 3-ESPIROCICLICA AS AGRONISTS OF GHRELINE RECEPTORS
MA20150428A1 (en)	2012-05-03	2015-11-30	Novartis Ag	L-malate salt of 2,7-diaza-spiro [4.5] dec-7-yl derivatives and its crystalline forms as ghrelin receptor agonists
CA3197470A1 (en)	2020-10-21	2022-04-28	Aligos Therapeutics, Inc.	Bicyclic compounds
US11957683B2 (en)	2021-06-18	2024-04-16	Aligos Therapeutics, Inc.	Bicyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW432073B (en) *	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
WO1998058947A1 (en) *	1997-06-25	1998-12-30	Pfizer Inc.	Dipeptide derivatives as growth hormone secretagogues

2001
- 2001-04-26 DO DO2001000154A patent/DOP2001000154A/en unknown
- 2001-05-10 CA CA002408036A patent/CA2408036A1/en not_active Abandoned
- 2001-05-10 MX MXPA02011554A patent/MXPA02011554A/en unknown
- 2001-05-10 AU AU2001255013A patent/AU2001255013A1/en not_active Abandoned
- 2001-05-10 WO PCT/IB2001/000815 patent/WO2001089570A2/en not_active Application Discontinuation
- 2001-05-10 JP JP2001585812A patent/JP2003534294A/en active Pending
- 2001-05-10 BR BR0111002-0A patent/BR0111002A/en not_active Application Discontinuation
- 2001-05-10 EP EP01928149A patent/EP1284753A2/en not_active Withdrawn
- 2001-05-17 GT GT200100089A patent/GT200100089A/en unknown
- 2001-05-18 US US09/860,786 patent/US20020002137A1/en not_active Abandoned
- 2001-05-23 PE PE2001000472A patent/PE20011262A1/en not_active Application Discontinuation
- 2001-05-24 TN TNTNSN01076A patent/TNSN01076A1/en unknown
- 2001-05-24 PA PA20018517701A patent/PA8517701A1/en unknown
- 2001-05-24 SV SV2001000465A patent/SV2001000465A/en unknown
- 2001-05-24 EC EC2001004082A patent/ECSP014082A/en unknown
- 2001-05-24 AR ARP010102481A patent/AR028620A1/en not_active Application Discontinuation
- 2001-05-25 UY UY26731A patent/UY26731A1/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20020002137A1 (en)	2002-01-03
BR0111002A (en)	2003-04-15
WO2001089570A3 (en)	2002-06-20
PE20011262A1 (en)	2001-12-11
EP1284753A2 (en)	2003-02-26
GT200100089A (en)	2002-01-11
ECSP014082A (en)	2002-04-23
CA2408036A1 (en)	2001-11-29
UY26731A1 (en)	2001-12-28
PA8517701A1 (en)	2002-12-30
AR028620A1 (en)	2003-05-14
SV2001000465A (en)	2001-07-03
WO2001089570A2 (en)	2001-11-29
MXPA02011554A (en)	2003-04-25
JP2003534294A (en)	2003-11-18
TNSN01076A1 (en)	2005-11-10
DOP2001000154A (en)	2002-05-15

Publication	Publication Date	Title
AU2001229712A1 (en)	2001-08-07	Reduction of hair growth
AU2001293178A1 (en)	2002-04-08	Dental implant system and additional methods of attachment
EP1291377B8 (en)	2007-06-13	Silicone compound and cosmetic preparation
AU2001294876A1 (en)	2002-04-08	Direct growth of nanotubes, and their use in nanotweezers
AU2001229363A1 (en)	2001-07-31	Antisense modulation of caspase 3 expression
ZA986822B (en)	1999-02-02	Reduction of hair growth
AU2001253411A1 (en)	2001-11-26	Medical dressing assembly and associated method of using the same
AU7907300A (en)	2001-04-30	Novel combination of loteprednol and antihistamines
IL137491A0 (en)	2001-07-24	Combination preparation of oestrogen and antioestrogen
AU6606601A (en)	2001-12-24	Growth hormone secretagogues
AU2002225954A1 (en)	2002-05-21	Dipeptidylpeptidases and methods of use
HUP0103072A3 (en)	2003-07-28	Use of growth hormone secretagogues
AU2001255013A1 (en)	2001-12-03	Combination of growth hormone secretagogues and antidepressants
AU6723401A (en)	2002-01-08	Antimicrobial peptides and methods of use thereof
AU2002210916A1 (en)	2002-04-29	Endoscope attachment and endoscope
AU2001227848A1 (en)	2001-07-31	Antisense modulation of caspase 8 expression
AU2001289068A1 (en)	2002-04-02	Antisense modulation of caspase 2 expression
EP1086215A4 (en)	2005-10-19	Preparation and use of superior vaccines
PL353487A1 (en)	2003-11-17	Novel combination of loteprednol and beta2
AU2001264863A1 (en)	2001-12-03	Preparation of fagopyritols and uses therefor
AU7410900A (en)	2001-03-19	Alginate preparation and use of the same
AU2001277696A1 (en)	2002-02-13	Novel physiologically active peptide and use thereof
AU2002230129A1 (en)	2002-08-19	Novel physiologically active peptide and use thereof
AUPQ760400A0 (en)	2000-06-08	Herbical formulations and methods of use thereof
AU2001277519A1 (en)	2002-01-21	Bio-probes and use thereof